188 related articles for article (PubMed ID: 25410895)
1. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.
Silvestris N; Vincenzi B; Brunetti AE; Loupakis F; Dell'Aquila E; Russo A; Scartozzi M; Giampieri R; Cascinu S; Lorusso V; Tonini G; Falcone A; Santini D
Pharmacogenomics; 2014 Sep; 15(13):1701-15. PubMed ID: 25410895
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
Bardelli A; Siena S
J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
4. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
5. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
8. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
9. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
11. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
12. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
13. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M
Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
16. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
[TBL] [Abstract][Full Text] [Related]
17. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
[No Abstract] [Full Text] [Related]
18. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Loupakis F; Di Maio M; Falcone A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
[No Abstract] [Full Text] [Related]
19. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
20. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
